A subgroup of patients with atopic dermatitis (AD) do not show sufficient improvement with current systemic therapies, highlighting the heterogeneity of the chronic inflammatory skin disease and the need for novel treatments.

Atopic dermatitis (AD) is a chronic, inflammatory skin disease where increased IL-22 expression contributes to epidermal hyperplasia and barrier defects. Temtokibart is a monoclonal antibody targeting the IL-22RA1, blocking the signaling of IL-22, and potentially also of IL-20 and IL-24.

Stage 1 of the OUtMATCH study demonstrated treatment with omalizumab for 16-20 weeks significantly increased the reaction threshold for peanut and other common food allergens in participants with multiple food allergies. However, the degree of this protection is variable across participants and there are no known markers to predict or assess individual response to omalizumab.

Polyp recurrence (PR) can occur in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) following endoscopic sinus surgery (ESS). We previously constructed a PR prediction model incorporating tissue biomarkers, including eosinophil cationic protein (ECP), IL-5, and anti-double-stranded DNA IgG, as well as clinical variables including the pre-ESS modified Lund-Mackay radiographic score and asthma status.

Patients with common variable immunodeficiency (CVID) suffer from hypogammaglobulinemia linked to an inadequate differentiation of long-lived humoral immunity and an impaired germinal center (GC) response in the majority of cases.

SARS-CoV-2-triggered autoantibodies (AAB) targeting G protein-coupled receptors (GPCRs) have been suggested to contribute to the post-acute sequelae of COVID-19 (Post-COVID-19 Syndrome, PCS).

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most consumed medicines worldwide and the main drug hypersensitivity triggers. The most common type is bred by pharmacologic cyclooxygenase-1 (COX-1) inhibition, after chemically unrelated NSAID intake, and NSAID-induced acute urticaria/angioedema (NIUA) is the most frequent clinical phenotype, with patients being frequently sensitized (atopic) to Dermatophagoides pteronyssinus (DP).

Eosinophilic inflammation represents a hallmark pathological feature of Chronic rhinosinusitis with nasal polyps (CRSwNP). Although ceramides, the central sphingolipid metabolites, are implicated in asthma pathogenesis, their mechanistic contributions to CRSwNP remain poorly elucidated.

Peanut allergy is a common condition without a cure. Oral immunotherapy (OIT) induces desensitization, but its mechanisms are not fully understood.

Inborn errors of immunity (IEI), or primary immune disorders (PIDs), predispose individuals to infections, autoimmunity, inflammation, allergy, and malignancy. Malignancies are a major cause of morbidity and mortality in patients with IEI/PIDs, with poorer outcomes compared with the general population.

Transient increases in blood eosinophil count (BEC) have been observed in dupilumab clinical trials but are rarely associated with clinical symptoms.

Disparities in asthma morbidity between Black and non-Hispanic White children are well-documented, but less is known about differences between Mexican American and non-Hispanic White children.